1 Introduction Antibody-drug conjugates (ADC) are an emerging technology that selectively targets cancer cells to overcome the limitations of chemotherapy. ADC binds to antigens, especially those overexpressed on the surface of cancer cells, reducing side effects caused by nonspecific targeting and improving the therapeutic index. The ideal efficacy of an ADC is entirely dependent on … Read more
Antibody-drug conjugates (ADC) are a class of targeted cancer therapies that combine the high specificity of monoclonal antibodies with the potent activity of small molecule cytotoxic drugs to enhance tumor targeting and reduce side effects. Compared to traditional antibodies or antibody fragments, ADCs theoretically have higher efficacy due to their ability to release highly active … Read more
Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies (mAbs) with small molecule drugs through linkers. The specificity of mAbs for tumor cells allows small molecule drugs to act effectively within tumor tissues, significantly reducing the high toxicity and side effects of traditional small molecule drugs while improving overall therapeutic efficiency. Currently, there are 13 … Read more
Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies (mAbs) with small molecule drugs through linkers. The specificity of mAbs for tumor cells allows small molecule drugs to act effectively within tumor tissues, significantly reducing the high toxic side effects of traditional small molecule drugs and enhancing overall therapeutic efficiency. Currently, there are 13 ADC … Read more
Antibody-drug conjugates (ADCs) consist of linkers, payloads, and monoclonal antibodies (mAbs). They combine the advantages of high specificity targeting and potent cytotoxic effects, achieving precise and efficient elimination of cancer cells, making them a hot topic in cancer drug development. Since the first ADC drug Mylotarg® was approved by the FDA in 2000, as of … Read more
Introduction Antibody-Drug Conjugates (ADCs) are targeted therapies that consist of antibodies, linkers, and cytotoxic drugs, using monoclonal antibodies as carriers to efficiently deliver cytotoxic drugs to target tumor cells in a targeted manner, combining the powerful killing effect of traditional chemotherapy with the tumor-targeting capability of antibody drugs. An ideal ADC maintains stability in the … Read more
Source: Xiaoyao Shuo Yao Introduction Antibody-drug conjugates (ADC) are a powerful cancer treatment method that combines monoclonal antibodies targeting specific antigens with small molecule cytotoxic drugs linked by a linker. ADCs utilize the specificity of antibodies for their target antigens, combined with the potency of cytotoxic drugs, to selectively kill tumor cells expressing the target … Read more
Photodynamic therapy (PDT), as a non-invasive treatment for tumors, has garnered widespread attention. However, the hypoxia of solid tumors, the skin phototoxicity of “always-on” photosensitizers (PSs), and the abundant supply of glutathione (GSH) in cancer cells severely hinder the clinical application of PDT. To address this issue, the team from the First Affiliated Hospital of … Read more
Programmed cell death (PCD) plays a crucial role in triggering tumor cell death in the forefront of biomedical research. However, due to various drug resistance mechanisms in cancer, malignant tumor cells often develop resistance to commonly used apoptosis-inducing anticancer drugs. Considering that mitochondria are the sources of aerobic respiration and reactive oxygen species (ROS), we … Read more
With DS8201 continuously dominating the field of HER-2 solid tumors such as breast cancer, gastric cancer, and lung cancer, the pressure on other HER2-ADCs is increasing day by day. Faced with a suddenly strong competitor, various HER2-ADC manufacturers have their own responses; some choose to join forces when they cannot compete, quickly following in the … Read more